Clinical trials of exon skipping in Duchenne muscular dystrophy

References

• Koenig M, Hoffman EP, Bertelson CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987 Jul 31;50(3):509–517.
   Google Scholar
• Van Deutekom JC, Bremmer-Bout M, Janson AA, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 2001;10:1547–1554.
   Google Scholar
• Wilton SD, Lloyd F, Carville K, et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides, Neuromuscul. Disord. 1999;5:330–338.
   Google Scholar
• Matsuo M. Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy. Brain Dev. 1996;18:167–172.
   Google Scholar
• Lu QL, Mann CJ, Lou F, et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med. 2003;9:1009–1014.
   Google Scholar
• Aartsma-Rus A, Fokkema I, Verschuuren J, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat. 2009;30:293–299.
   Google Scholar
• Frazier KS, Sobry C, Derr V, et al. Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide. Toxicol Pathol. 2014;42:923–935.
   Google Scholar
• Lee KW, Kim DS, Kwon HJ. CG sequence- and phosphorothioate backbone modification-dependent activation of the NF-kappaB-responsive gene expression by CpG-oligodeoxynucleotides in human RPMI 8226 B cells. Mol Immunol. 2004;41:955–964.
   Google Scholar
• Van Deutekom JC, Janson AA, Ginjaar LB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007;357:2677–2686.
   Google Scholar
• Goemans NM, Tulinius M, Van Den Akker JT, et al. Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N Engl J Med. 2011;364:1513–1522.
   Google Scholar
• Voit T, Topaglu H, Straub V, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014;13:987–996.
   Google Scholar
• Carroll J. Muscular dystrophy drug from GlaxoSmithKline, Prosensa fails PhI/II. FierceBiotechol. 2013;09:20. http://www.fiercebiotech.com/story/muscular-dystrophy-drug-glaxosmithkline-prosensa-fails-phiii/2013-09-20
   Google Scholar
• Flanigan KM, Voit T, Rosales XQ, et al. Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial. Neuromuscul Disord. 2014;24:16–24.
   Google Scholar
• Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009;8:918–928.
   Google Scholar
• Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011;378:595–605.
   Google Scholar
• Lai Y, Thomas GD, Yue Y, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest. 2009;119:624–635.
   Google Scholar
• Krieger CC, Bhasin N, Tewari M, et al. Exon-skipped dystrophins for treatment of Duchenne muscular dystrophy: mass spectrometry mapping of most exons and cooperative domain designs based on single molecule mechanics. Cytoskeleton. 2010;67:796–807.
   Google Scholar
• Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74:637–647.
   Google Scholar
• Fitzgerald S, Approves Controversial FDA. DMD drug amid scientific controversy and advocates’ pleas. Neurol Today. 2016;8–12.
   Google Scholar
• Mendell JR, Goemans N, Lowes L, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016;79:257–271.
   Google Scholar
• Khirani S, Ramirez A, Aubertin G, et al. Respiratory muscle decline in Duchenne muscular dystrophy. Pediatr Pulmonol. 2014;49:473–481.
   Google Scholar
• Mayer OH, Finkel RS, Rummey C, et al. Characterization of pulmonaryfunction in Duchenne muscular dystrophy. Pediatr Pulmonol. 2015;50:487–494.
   Google Scholar
• Pane M, Mazzone ES, Sivo S, et al. Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS One. 2014;9:e108205.
   Google Scholar
• Goemans N, Van Den Hauwe M, Wilson R, et al. Ambulatory capacity and disease progression as measured by the 6-minutewalk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscul Disord. 2013;23:618–623.
   Google Scholar
• McDonald CM, Henricson EK, Abresch RT, et al. The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve. 2013;48:357–368.
   Google Scholar
• Muntoni F, Bushby KD, Van Ommen G. 149th ENMC International Workshop and 1st TREAT-NMD Workshop on: “planning phase I/II clinical trials using systemically delivered antisense oligonucleotides in Duchenne muscular dystrophy”. Neuromuscul Disord. 2008;18:268–275.
   Google Scholar
• Betts C, Saleh AF, Arzumanov AA, et al. Pip6-PMO, A new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD Treatment. Mol Ther Nucleic Acids. 2012 Aug 14;1:e38.
   Google Scholar
• Echigoya Y, Nakamura A, Nagata T, et al. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA. 2017;114:4213–4218.
   Google Scholar